<DOC>
	<DOCNO>NCT00684645</DOCNO>
	<brief_summary>Primary objective : increase knowledge safety , tolerability , quality life efficacy condition routine use SUTENT® . Secondary objective : treatment response , hypothyroidism prevalence.The efficacy assess use Objective Response Rate , Time Progression base RECIST criterion ECOG performance data .</brief_summary>
	<brief_title>Non-Interventional Study ( NIS ) In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma ( mRCC ) Treated With SUTENT®</brief_title>
	<detailed_description>180 patient enrol 20 key oncological centre , sample size sufficient exploratory analysis .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>Patients advance metastatic renal cell carcinoma . No previous cytokine therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Safety tolerability SUTENT® patient metastatic advance renal cell carcinoma failure cytokine real-life setting .</keyword>
</DOC>